Literature DB >> 18479486

Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.

Anastasia Ivanova1, Se Hee Kim.   

Abstract

In many phase I trials, the design goal is to find the dose associated with a certain target toxicity rate. In some trials, the goal can be to find the dose with a certain weighted sum of rates of various toxicity grades. For others, the goal is to find the dose with a certain mean value of a continuous response. In this article, we describe a dose-finding design that can be used in any of the dose-finding trials described above, trials where the target dose is defined as the dose at which a certain monotone function of the dose is a prespecified value. At each step of the proposed design, the normalized difference between the current dose and the target is computed. If that difference is close to zero, the dose is repeated. Otherwise, the dose is increased or decreased, depending on the sign of the difference.

Entities:  

Mesh:

Year:  2008        PMID: 18479486      PMCID: PMC2819822          DOI: 10.1111/j.1541-0420.2008.01045.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  18 in total

1.  Improved up-and-down designs for phase I trials.

Authors:  Anastasia Ivanova; Aliakbar Montazer-Haghighi; Sri Gopal Mohanty; Stephen D Durham
Journal:  Stat Med       Date:  2003-01-15       Impact factor: 2.373

2.  Continuous toxicity monitoring in phase II trials in oncology.

Authors:  Anastasia Ivanova; Bahjat F Qaqish; Michael J Schell
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

3.  Adaptive dose finding based on t-statistic for dose-response trials.

Authors:  Anastasia Ivanova; James A Bolognese; Inna Perevozskaya
Journal:  Stat Med       Date:  2008-05-10       Impact factor: 2.373

Review 4.  Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study.

Authors:  J O'Quigley; S Chevret
Journal:  Stat Med       Date:  1991-11       Impact factor: 2.373

5.  A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.

Authors:  B Nebiyou Bekele; Yu Shen
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

6.  Practical modifications of the continual reassessment method for phase I cancer clinical trials.

Authors:  D Faries
Journal:  J Biopharm Stat       Date:  1994-07       Impact factor: 1.051

7.  Comparison of Isotonic Designs for Dose-Finding.

Authors:  Anastasia Ivanova; Nancy Flournoy
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

8.  Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors:  J Babb; A Rogatko; S Zacks
Journal:  Stat Med       Date:  1998-05-30       Impact factor: 2.373

9.  The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

Authors:  Z Yuan; R Chappell; H Bailey
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

10.  An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers.

Authors:  John Whitehead; Yinghui Zhou; Adrian Mander; Sally Ritchie; Antony Sabin; Andrew Wright
Journal:  Stat Med       Date:  2006-02-15       Impact factor: 2.373

View more
  17 in total

1.  Incorporating lower grade toxicity information into dose finding designs.

Authors:  Alexia Iasonos; Sarah Zohar; John O'Quigley
Journal:  Clin Trials       Date:  2011-08       Impact factor: 2.486

2.  Continual reassessment method with multiple toxicity constraints.

Authors:  Shing M Lee; Bin Cheng; Ying Kuen Cheung
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

3.  Dose-finding designs for cumulative toxicities using multiple constraints.

Authors:  Shing M Lee; Moreno Ursino; Ying Kuen Cheung; Sarah Zohar
Journal:  Biostatistics       Date:  2019-01-01       Impact factor: 5.899

4.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

Review 5.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

6.  Sequential designs for individualized dosing in phase I cancer clinical trials.

Authors:  Xuezhou Mao; Ying Kuen Cheung
Journal:  Contemp Clin Trials       Date:  2016-08-31       Impact factor: 2.226

7.  Up-and-down designs for phase I clinical trials.

Authors:  Suyu Liu; Chunyan Cai; Jing Ning
Journal:  Contemp Clin Trials       Date:  2013-07-13       Impact factor: 2.226

8.  Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.

Authors:  Changfu Xiao; Anastasia Ivanova
Journal:  J Stat Plan Inference       Date:  2012-07-01       Impact factor: 1.111

9.  Risk-group-specific dose finding based on an average toxicity score.

Authors:  B Nebiyou Bekele; Yisheng Li; Yuan Ji
Journal:  Biometrics       Date:  2009-07-23       Impact factor: 2.571

10.  Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs.

Authors:  Anastasia Ivanova; Changfu Xiao
Journal:  Pharm Stat       Date:  2013-07-26       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.